Exom named Finalist of the SCRIP AWARDS 2019 in “Best Technological Development in Clinical Trials”

Exom Group, the Global Digital Full-Service CRO, proudly announces that its digital platform Genius ROSA has been nominated Finalist of the Scrip Awards 2019 edition for the category “Best Technological Development in Clinical Trials”. “This nomination confirms the value of Exom’s innovative strategy in implementing novel digital solutions into clinical trials, to better satisfy the industry expectations”, says Luigi Visani MD, President & CEO of Exom Group.

Genius ROSA is Exom’s sophisticated telemonitoring platform enabling investigators to regularly monitor patients at home and measure patient-centric clinical outcomes through mobile devices at any time during a clinical trial. “We are very proud that this solution is so well recognized by the market.” - Visani continues – “Besides collecting data at the patient’s home, a familiar environment to study participants, Genius ROSA knocks down geographical barriers by enabling the participation of those patients who live far away from the study site or who are unable to travel, such as elderly people, disabled persons, or children and infants”.

Visani emphasizes that “Genius ROSA is the ideal solution for the patient-centric study model because of the proper delivery of out-of-hospital services, and collection of home-recorded data, based on care solutions tailored to each study. Ultimately the BYOD approach, by allowing patients to use their own mobile device, provides a cost-effective, quick-start and resource-efficient tool of remote patient monitoring.”

“Exom is bringing forward the modernization of clinical trial processes through the implementation of disruptive digital solutions”, says Visani. “And this nomination shows that weare going in the right direction. We will continue to develop and offer the most innovative services and solutions to our clients.”, he concluded.

About Exom
Exom is a European based CRO, which is committed to improving the performance of clinical trials through Digital Transformation and Patient Engagement. By combining its expertise across medical, regulatory and operational functions with its proprietary, multi-modular and cloud-based platform Genius SUITE™, Exom improves efficiencies and escalate process speeds while ensuring data quality and costs reduction, from Early Phase to Late Phase & Outcome Studies.

About Reply Healthcare
Reply is made up of a network of highly specialized companies, which support leading industrial groups in defining and developing business models to optimize and integrate processes, applications and devices, using new technology and communication paradigms, such as Big Data; Cloud Computing; Digital Communication; Internet of Things; Mobile and Social Networking. Reply’s offer covers three areas of competence: Processes, Applications and Technologies.

Contact Information

Patrick McManus
Chief Development Officer
Mobile: +49 (0)172 941 2912



twitter @exomgroup

Exom ist das digitale Full-Service CRO, das sich der Modernisierung klinischer Studien durch die Implementierung innovativer digitaler L... [mehr]